| News

docdok.health involved in coronavirus research project

22.02.2021

A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.

img: docdok.health

According to a media release, the new research project on the effects of coronavirus infection has been launched by the CAir Konsortium, which includes the University Hospital Zurich (USZ) and the Swiss Federal Institute of Technology in Zurich (ETH) in addition to docdok.health, among others. The media release from docdok.health states that the project is also being supported by AstraZeneca Switzerland. With this, the research partners hope to investigate “the improvement in symptoms, lung function and quality of life in persons who have been hospitalized due to a coronavirus (specifically SARS-CoV-2) infection and the related severe lung disease to lung failure.”

For this, patients were surveyed after being discharged from the USZ using a docdok.health smartphone app, and a home monitoring system was implemented to follow-up patients. This system consists of “a lung function measuring device, an activity wristband, an air quality monitor, and a smartphone.” This system, called CAir Desk, was originally developed for the long-term care of patients with chronic lung disease.

Physicians from the USZ are able to study the data from both approaches at their place of work. For this, the data is prepared by docdok.health and presented clearly on an appropriate user interface. The company based in Basel was founded in 2017 and develops solutions to drive forward utility-based healthcare. The platform they have developed can collect and prepare patient-generated health data. This platform is already in use in five countries both for routine clinical applications and studies.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Hemex attracts Swiss investors
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Hemex attracts Swiss investors

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for Hemex. The...

Read More
Rhizen drug secures approval in the USA
Basel Area Business & Innovation, Innovation, Invest

Rhizen drug secures approval in the USA

The United States Food and Drug Administration has granted accelerated approval for the drug Umbralisib. Basel biotech Rhizen has discovered...

Read More
Novaremed secures US$50 million
Basel Area Business & Innovation, Innovation, Invest

Novaremed secures US$50 million

Basel biotech Novaremed is receiving US$50 million through an agreement with an investment group. Novaremed will use this financing to...

Read More
Axtria driving growth from Basel
Basel Area Business & Innovation, Innovation, Invest

Axtria driving growth from Basel

The US firm Axtria has established a new office in Basel. The company offers services for the life sciences industry...

Read More
Technologiepark Basel celebrates its role as a driver of innovation
Basel Area Business & Innovation, Innovation, Invest

Technologiepark Basel celebrates its role as a driver of innovation

The Technologiepark Basel will be ten years old in 2021. Over the past decade, it has supported many startups and...

Read More
Basel Area has ever more to offer investors
Basel Area Business & Innovation, Innovation, Invest

Basel Area has ever more to offer investors

The canton of Basel-Stadt has displayed the most striking performance in the Swiss Venture Capital Report. Last year, more than...

Read More
1 2 3 7

Do you have a question? We'd like to hear from you.